1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
Delayed Toronto Stock Exchange  -  05/20 04:00:00 pm EDT
5.310 CAD   +1.92%
05/12Knight Therapeutics Reports Q1 Loss Per Share $0.16, Updates Revenue Guidance
MT
05/12TRANSCRIPT : Knight Therapeutics Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
5.2(c) 5.23(c) 5.19(c) 5.21(c) 5.31(c) Last
121 242 97 841 168 121 64 642 119 183 Volume
-0.38% +0.58% -0.76% +0.39% +1.92% Change
More quotes
Estimated financial data (e)
Sales 2022 266 M 207 M 207 M
Net income 2022 -27,8 M -21,7 M -21,7 M
Net Debt 2022 - - -
P/E ratio 2022 -22,0x
Yield 2022 -
Sales 2023 297 M 231 M 231 M
Net income 2023 8,62 M 6,71 M 6,71 M
Net Debt 2023 - - -
P/E ratio 2023 -295x
Yield 2023 -
Capitalization 612 M 477 M 477 M
Capi. / Sales 2022 2,30x
Capi. / Sales 2023 2,06x
Nbr of Employees 660
Free-Float 81,2%
More Financials
Company
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA... 
Sector
Pharmaceuticals
Calendar
08/11Earnings Release
More about the company
Ratings of Knight Therapeutics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about KNIGHT THERAPEUTICS INC.
05/12Knight Therapeutics Reports Q1 Loss Per Share $0.16, Updates Revenue Guidance
MT
05/12TRANSCRIPT : Knight Therapeutics Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/12Knight Therapeutics Reports First Quarter 2022 Results
GL
05/12Knight Therapeutics Reports First Quarter 2022 Results
GL
05/12Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2022
CI
05/12Knight Therapeutics and Helsinn Healthcare SA Enters into Exclusive License, Distributi..
CI
05/12Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distributio..
GL
05/12Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distributio..
AQ
05/11Knight to Present at the 2022 RBC Capital Markets Global Healthcare Conference in New Y..
GL
05/11Knight Therapeutics Inc. announces voting results from the Annual Meeting
GL
05/11Knight Therapeutics Inc. announces voting results from the Annual Meeting
GL
05/11TRANSCRIPT : Knight Therapeutics Inc. - Shareholder/Analyst Call
CI
05/05Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call
GL
05/05Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call
AQ
More news
News in other languages on KNIGHT THERAPEUTICS INC.
05/12Knight Therapeutics annonce une perte par action de 0,16 $ au premier trimestre et met ..
05/12Knight Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mar..
05/12Thérapeutique Knight publie ses résultats du premier trimestre 2022
05/12Knight Therapeutics Inc. fournit des prévisions de revenus pour l'année fiscale 2022
05/12Knight Therapeutics et Helsinn Healthcare SA concluent un accord exclusif de licence, d..
More news
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,31 CAD
Average target price 7,00 CAD
Spread / Average Target 31,8%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
Monica Percario Vice President-Global Scientific Affairs
Daniela Marino Marino Vice President-Legal and Compliance
Sector and Competitors
1st jan.Capi. (M$)
KNIGHT THERAPEUTICS INC.0.19%477
MERCK KGAA-24.05%79 076
KYOWA KIRIN CO. LTD.-13.65%11 377
SK BIOPHARMACEUTICALS CO., LTD.-11.21%5 308
YUHAN CORPORATION-5.80%3 126
BETTA PHARMACEUTICALS CO., LTD.-43.32%2 808